Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Other Accumulated Expenses (2020 - 2025)

Historic Other Accumulated Expenses for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $1.7 million.

  • Tango Therapeutics' Other Accumulated Expenses fell 3703.57% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 3703.57%. This contributed to the annual value of $1.7 million for FY2024, which is 3480.96% up from last year.
  • Tango Therapeutics' Other Accumulated Expenses amounted to $1.7 million in Q3 2025, which was down 3703.57% from $2.0 million recorded in Q2 2025.
  • Tango Therapeutics' 5-year Other Accumulated Expenses high stood at $2.7 million for Q3 2024, and its period low was $666000.0 during Q4 2021.
  • For the 5-year period, Tango Therapeutics' Other Accumulated Expenses averaged around $1.5 million, with its median value being $1.5 million (2023).
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first soared by 9082.7% in 2024, then plummeted by 3703.57% in 2025.
  • Quarter analysis of 5 years shows Tango Therapeutics' Other Accumulated Expenses stood at $666000.0 in 2021, then soared by 90.24% to $1.3 million in 2022, then rose by 1.58% to $1.3 million in 2023, then surged by 34.81% to $1.7 million in 2024, then fell by 0.35% to $1.7 million in 2025.
  • Its Other Accumulated Expenses stands at $1.7 million for Q3 2025, versus $2.0 million for Q2 2025 and $2.0 million for Q1 2025.